473 related articles for article (PubMed ID: 15868119)
1. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
Barnett AH
Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
[TBL] [Abstract][Full Text] [Related]
2. Prevention of loss of renal function over time in patients with diabetic nephropathy.
Barnett A
Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
[TBL] [Abstract][Full Text] [Related]
3. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Barnett A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
Rippin J; Bain SC; Barnett AH;
J Diabetes Complications; 2002; 16(3):195-200. PubMed ID: 12015188
[TBL] [Abstract][Full Text] [Related]
6. Reduction of proteinuria with angiotensin receptor blockers.
Galle J
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
[TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Nakamura T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H
Eur J Clin Invest; 2010 Sep; 40(9):790-6. PubMed ID: 20584070
[TBL] [Abstract][Full Text] [Related]
8. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
Zidek W
MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706
[No Abstract] [Full Text] [Related]
9. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
Ravid M; Lang R; Rachmani R; Lishner M
Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Sengul AM; Altuntas Y; Kürklü A; Aydin L
Diabetes Res Clin Pract; 2006 Feb; 71(2):210-9. PubMed ID: 16112244
[TBL] [Abstract][Full Text] [Related]
11. Low-dose angiotensin converting enzyme inhibitors: effect on renal function in normo- and hypertensive type 1 diabetic patients.
Ciavarella A; Mustacchio A; Silletti A; Franchi R; Levorato M; Campieri C; Borgnino LC; Capozzi G; Morotti L; Vannini P
Eur J Med; 1992 Sep; 1(5):268-72. PubMed ID: 1341608
[TBL] [Abstract][Full Text] [Related]
12. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
13. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
14. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
[No Abstract] [Full Text] [Related]
15. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
Mazerska M; Myśliwiec M
Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
Weinbergová O; Metelka R; Vymetal J; Konecný K; Kosatíková Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):69-73. PubMed ID: 15523550
[TBL] [Abstract][Full Text] [Related]
17. Renal protection in diabetes: lessons from ONTARGET.
Ritz E; Schmieder RE; Pollock CA
Cardiovasc Diabetol; 2010 Oct; 9():60. PubMed ID: 20920303
[TBL] [Abstract][Full Text] [Related]
18. ACE-I and ARBs in early diabetic nephropathy.
Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan in incipient and overt diabetic renal disease.
Schmieder RE; Bakris G; Weir MR
J Nephrol; 2011; 24(3):263-73. PubMed ID: 21374585
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
